People: Compugen Ltd (CGEN.OQ)
17 Sep 2019
Dr. Henry Adewoye is Chief Medical Officer of the Company. Dr. Adewoye joins Compugen from Gilead Sciences Inc., where he most recently served as Clinical Director in Oncology Clinical Research, was on the Oncology Leadership Team and held positions of increasing responsibility as Project Team and Clinical Lead for multiple Phase 1-3 Programs (Idelalisib - the first PI3 kinase delta inhibitor approved for relapsed CLL, SLL and Follicular lymphoma), Andecaliximab (MMP-9 inhibitor), GS-9901, and Acalisib. Prior to Gilead, he was Clinical Research Medical Director in Oncology at Amgen Inc. and Global Medical Monitor for the initial registrational trial of the bispecific antibody blinatumomab (Blincyto®) and several Phase 2 and 3 studies evaluating VEGF inhibitors (motesanib, trebananib) in patients with solid tumors. Dr. Adewoye completed his Fellowship in Hematology/Oncology at Boston Medical Center and completed his residency in Internal Medicine atMeharry Medical College. Dr. Adewoye received his medical degree at the University of Jos,Nigeriaand Fellowship training in hematology and laboratory medicine at the University College Hospital Ibadan,Nigeria. Dr Adewoye is Board Certified by the American Board of Internal Medicine in Medical Oncology, Hematology and Internal Medicine.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|